WPC
NBIX icon

Wedmont Private Capital’s Neurocrine Biosciences NBIX Stock Holding History

Wedmont Private Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Buy
1,676
+35
+2% +$5.19K 0.01% 744
2026
Q1 		$218K Buy
1,641
+18
+1% +$2.39K 0.01% 780
2025
Q4 		$228K Buy
+1,623
New +$235K 0.01% 740

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Wedmont Private Capital's NBIX Position: Q2 2026 in Review

Wedmont Private Capital increased its Neurocrine Biosciences (NBIX) stake by 2.1% in Q2 2026, buying an estimated $5.19K and bringing the position to 1,676 shares worth $297K. The position accounts for 0.01% of the portfolio, ranked #744.

Wedmont Private Capital first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Wedmont Private Capital held 1,676 shares of Neurocrine Biosciences worth $297K as of Q2 2026.
  • Wedmont Private Capital bought 35 Neurocrine Biosciences shares in Q2 2026, an estimated $5.19K.
  • Neurocrine Biosciences made up 0.01% of Wedmont Private Capital's portfolio in Q2 2026, its #744 holding.
  • Wedmont Private Capital first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.